| Erkrankung: | Brustkrebs (Mammakarzinom) |
| Status der Studie: | Studie rekrutiert |
| Studiendesign: | interventionell |
| Studienphase: | Phase IV |
| Studienart: | Medikamentöse Therapie |
| Haupteinschlusskritieren: | 1. Post- or pre/peri-menopausal female patients, age ≥18 years 2. Patients with metastatic or locally advanced (non-operable) breast cancer disease 3. Patients who are appropriate candidates for aromatase inhibitor + palbociclib combination therapy OR Patients having already received endocrine therapy who are appropriate candidates for fulvestrant+ palbociclib combination therapy: 4. Patient has not received treatment for locally advanced or metastatic disease OR Patient has received one prior line of chemotherapy and/or a maximum of two endocrine therapy lines for locally advanced or metastatic |
| Hauptausschlusskritieren: | 1. Known hypersensitivity to aromatase inhibitor, fulvestrant, palbociclib or any of its excipients 2. Contraindication for aromatase inhibitor, fulvestrant or palbociclib; or LHTH-agonists (if pre-menopausal) 3. Prior treatment with any CDK inhibitor. 4. Patients with locally advanced or metastatic, symptomatic, visceral spread, who are at risk of life threatening complications in the short term |
| Prüfarzt: | Dr. med. Antje Lehnert |
| Weitere Informationen: | Impact of eHealth-support on Quality of Life in metastatic breast cancer patients treated with Palbociclib and endocrine therapy |